Tumour immunity: effector response to tumour and role of the microenvironment
- PMID: 18275997
- DOI: 10.1016/S0140-6736(08)60241-X
Tumour immunity: effector response to tumour and role of the microenvironment
Abstract
Substantial evidence shows that inflammation promotes oncogenesis and, occasionally, participates in cancer rejection. This paradox can be accounted for by a dynamic switch from chronic smouldering inflammation promoting cancer-cell survival to florid, tissue-disruptive inflammatory reactions that trigger cancer-cell destruction. Clinical and experimental observations suggest that the mechanism of this switch recapitulates the events associated with pathogen infection, which stimulate immune cells to recognise danger signals and activate immune effector functions. Generally, cancers do not have danger signals and, therefore, they cannot elicit strong immune reactions. Synthetic molecules have been developed that mimic pathogen invasion at the tumour site. These compounds activate dendritic cells to produce proinflammatory cytokines, which in turn trigger cytotoxic mechanisms leading to cancer death. Simultaneously, dendritic cells capture antigen shed by dying cancer cells, undergo activation, and stimulate antigen-specific T and B cells. This process results in massive amplification of the antineoplastic inflammatory process. Thus, although anti-inflammatory drugs can prevent onset of some malignant diseases, induction of T cells specific for tumour antigen by active immunisation, combined with powerful activation signals within the cancer microenvironment, might yield the best strategy for treatment of established cancers.
Similar articles
-
Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.Scand J Immunol. 2004 Jul-Aug;60(1-2):143-52. doi: 10.1111/j.0300-9475.2004.01435.x. Scand J Immunol. 2004. PMID: 15238083
-
Genetically modified tumour vaccines--where we are today.Cancer Treat Rev. 1999 Feb;25(1):29-46. doi: 10.1053/ctrv.1998.0104. Cancer Treat Rev. 1999. PMID: 10212588 Review.
-
Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.Immunobiology. 2012 Jul;217(7):719-29. doi: 10.1016/j.imbio.2011.12.001. Epub 2011 Dec 8. Immunobiology. 2012. PMID: 22305004
-
Immunogenic anti-cancer chemotherapy as an emerging concept.Curr Opin Immunol. 2008 Oct;20(5):545-57. doi: 10.1016/j.coi.2008.05.008. Epub 2008 Jun 23. Curr Opin Immunol. 2008. PMID: 18573339 Review.
-
Antigen presentation at the inflammatory site.Crit Rev Immunol. 1989;9(4):313-62. Crit Rev Immunol. 1989. PMID: 2679663 Review.
Cited by
-
Prognostic value of innate and adaptive immunity in colorectal cancer.World J Gastroenterol. 2013 Jan 14;19(2):174-84. doi: 10.3748/wjg.v19.i2.174. World J Gastroenterol. 2013. PMID: 23345940 Free PMC article. Review.
-
Reactive oxygen species a double-edged sword for mesothelioma.Oncotarget. 2015 Jul 10;6(19):16848-65. doi: 10.18632/oncotarget.4253. Oncotarget. 2015. PMID: 26078352 Free PMC article. Review.
-
Predicting the unpredictable: a robust nomogram for predicting recurrence in patients with ampullary carcinoma.BMC Cancer. 2024 Feb 15;24(1):212. doi: 10.1186/s12885-024-11960-0. BMC Cancer. 2024. PMID: 38360582 Free PMC article.
-
The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.Br J Cancer. 2010 Sep 7;103(6):870-6. doi: 10.1038/sj.bjc.6605855. Epub 2010 Aug 17. Br J Cancer. 2010. PMID: 20717110 Free PMC article.
-
Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs.Mol Clin Oncol. 2013 Sep;1(5):805-810. doi: 10.3892/mco.2013.136. Epub 2013 May 30. Mol Clin Oncol. 2013. PMID: 24649250 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources